BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 33392838)

  • 1. Predictors and outcomes in breast cancer patients who did or did not pursue fertility preservation.
    Moravek MB; Confino R; Lawson AK; Smith KN; Kazer RR; Klock SC; Gradishar WJ; Jeruss JS; Pavone ME
    Breast Cancer Res Treat; 2021 Apr; 186(2):429-437. PubMed ID: 33392838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer-a prospective nationwide Swedish multicenter study.
    Marklund A; Eloranta S; Wikander I; Kitlinski ML; Lood M; Nedstrand E; Thurin-Kjellberg A; Zhang P; Bergh J; Rodriguez-Wallberg KA
    Hum Reprod; 2020 Apr; 35(4):929-938. PubMed ID: 32313940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Random start ovarian stimulation for fertility preservation appears unlikely to delay initiation of neoadjuvant chemotherapy for breast cancer.
    Letourneau JM; Sinha N; Wald K; Harris E; Quinn M; Imbar T; Mok-Lin E; Chien AJ; Rosen M
    Hum Reprod; 2017 Oct; 32(10):2123-2129. PubMed ID: 28938748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Safety of Letrozole and Gonadotropin Stimulation for Fertility Preservation in Women With Breast Cancer.
    Kim J; Turan V; Oktay K
    J Clin Endocrinol Metab; 2016 Apr; 101(4):1364-71. PubMed ID: 26751194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcomes in cancer patients who did or did not pursue fertility preservation.
    Moravek MB; Confino R; Smith KN; Kazer RR; Klock SC; Lawson AK; Gradishar WJ; Pavone ME
    Fertil Steril; 2018 Feb; 109(2):349-355. PubMed ID: 29338854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review.
    Rodgers RJ; Reid GD; Koch J; Deans R; Ledger WL; Friedlander M; Gilchrist RB; Walters KA; Abbott JA
    Hum Reprod; 2017 May; 32(5):1033-1045. PubMed ID: 28333356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of recurrence and pregnancy outcomes in young women with breast cancer who do and do not undergo fertility preservation.
    Wang Y; Tesch ME; Lim C; Xu YH; Lee S; Perdizet K; Yokom D; Warner E; Roberts J; Lohrisch CA
    Breast Cancer Res Treat; 2022 Sep; 195(2):201-208. PubMed ID: 35908122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fertility preservation before breast cancer treatment appears unlikely to affect disease-free survival at a median follow-up of 43 months after fertility-preservation consultation.
    Letourneau JM; Wald K; Sinha N; Juarez-Hernandez F; Harris E; Cedars MI; McCulloch CE; Dolezal M; Chien AJ; Rosen MP
    Cancer; 2020 Feb; 126(3):487-495. PubMed ID: 31639215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fertility Preservation Success Subsequent to Concurrent Aromatase Inhibitor Treatment and Ovarian Stimulation in Women With Breast Cancer.
    Oktay K; Turan V; Bedoschi G; Pacheco FS; Moy F
    J Clin Oncol; 2015 Aug; 33(22):2424-9. PubMed ID: 26101247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progesterone levels in letrozole associated controlled ovarian stimulation for fertility preservation in breast cancer patients.
    Goldrat O; Gervy C; Englert Y; Delbaere A; Demeestere I
    Hum Reprod; 2015 Sep; 30(9):2184-9. PubMed ID: 26109617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of controlled ovarian hyperstimulation with or without letrozole for fertility preservation in breast cancer patients: A multicenter retrospective study.
    Goldrat O; De Cooman M; Mailliez A; Delbaere A; D'Orazio E; Demeestere I; Decanter C
    Eur J Cancer; 2022 Oct; 174():134-141. PubMed ID: 35998549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovarian stimulation is a safe and effective fertility preservation option in the adolescent and young adult population.
    Manuel SL; Moravek MB; Confino R; Smith KN; Lawson AK; Klock SC; Pavone ME
    J Assist Reprod Genet; 2020 Mar; 37(3):699-708. PubMed ID: 31828481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The case for aromatase inhibitors use in oncofertility patients. Should aromatase inhibitors be combined with gonadotropin treatment in breast cancer patients undergoing ovarian stimulation for fertility preservation prior to chemotherapy? A debate.
    Fatum M; McVeigh E; Child T
    Hum Fertil (Camb); 2013 Dec; 16(4):235-40. PubMed ID: 23863119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian Stimulation Is Safe and Effective for Patients with Gynecologic Cancer.
    Akel RA; Guo XM; Moravek MB; Confino R; Smith KN; Lawson AK; Klock SC; Tanner Iii EJ; Pavone ME
    J Adolesc Young Adult Oncol; 2020 Jun; 9(3):367-374. PubMed ID: 31923372
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study.
    Azim AA; Costantini-Ferrando M; Oktay K
    J Clin Oncol; 2008 Jun; 26(16):2630-5. PubMed ID: 18509175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation.
    Oktay K; Buyuk E; Libertella N; Akar M; Rosenwaks Z
    J Clin Oncol; 2005 Jul; 23(19):4347-53. PubMed ID: 15824416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survey of young women with breast cancer to identify rates of fertility preservation (FP) discussion and barriers to FP care.
    Sauerbrun-Cutler MT; Pandya S; Recabo O; Raker C; Clark MA; Robison K
    J Assist Reprod Genet; 2023 Aug; 40(8):2003-2011. PubMed ID: 37329421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies.
    Meirow D; Raanani H; Maman E; Paluch-Shimon S; Shapira M; Cohen Y; Kuchuk I; Hourvitz A; Levron J; Mozer-Mendel M; Brengauz M; Biderman H; Manela D; Catane R; Dor J; Orvieto R; Kaufman B
    Fertil Steril; 2014 Aug; 102(2):488-495.e3. PubMed ID: 24934489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stimulation of the ovaries in women with breast cancer undergoing fertility preservation: Alternative versus standard stimulation protocols; the study protocol of the STIM-trial.
    Dahhan T; Balkenende EME; Beerendonk CCM; Fleischer K; Stoop D; Bos AME; Lambalk CB; Schats R; van Golde RJT; Schipper I; Louwé LA; Cantineau AEP; Smeenk JMJ; de Bruin JP; Reddy N; Kopeika Y; van der Veen F; van Wely M; Linn SC; Goddijn M
    Contemp Clin Trials; 2017 Oct; 61():96-100. PubMed ID: 28710053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of fertility preservation in breast cancer patients in a register-based matched cohort study.
    Rodriguez-Wallberg KA; Eloranta S; Krawiec K; Lissmats A; Bergh J; Liljegren A
    Breast Cancer Res Treat; 2018 Feb; 167(3):761-769. PubMed ID: 29098528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.